对《阿巴洛肽对绝经后骨质疏松症女性前臂骨矿物质密度和腕部骨折风险的影响》的更正
Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
作者信息
Watts N B, Hattersley G, Fitzpatrick L A, Wang Y, Williams G C, Miller P D, Cosman F
机构信息
Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA.
Radius Health, Inc., Waltham, MA, USA.
出版信息
Osteoporos Int. 2020 May;31(5):1017-1018. doi: 10.1007/s00198-020-05349-5.
Abstract
The original version of this article, published on 21 March 2019, unfortunately contained a mistake.
摘要
本文的原始版本于2019年3月21日发表，不幸的是存在一处错误。
相似文献
1
Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.对《阿巴洛肽对绝经后骨质疏松症女性前臂骨矿物质密度和腕部骨折风险的影响》的更正
Osteoporos Int. 2020 May;31(5):1017-1018. doi: 10.1007/s00198-020-05349-5.
2
Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.对《阿巴洛肽对绝经后骨质疏松症女性前臂骨矿物质密度和腕部骨折风险的影响》的更正
Osteoporos Int. 2020 Aug;31(8):1603-1605. doi: 10.1007/s00198-020-05469-y.
3
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.阿巴洛肽皮下注射对具有不同基线风险因素的绝经后骨质疏松症女性亚组骨折和骨密度的影响。
J Bone Miner Res. 2017 Jan;32(1):17-23. doi: 10.1002/jbmr.2991. Epub 2016 Sep 28.
4
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.阿巴洛肽与安慰剂对绝经后骨质疏松症妇女新发椎体骨折的影响：一项随机临床试验。
JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.
5
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.阿巴洛肽治疗后接受阿伦膦酸盐治疗的患者的骨折和骨密度反应按基线风险分层：来自 3 期 ACTIVExtend 试验的结果。
J Bone Miner Res. 2019 Dec;34(12):2213-2219. doi: 10.1002/jbmr.3848. Epub 2019 Sep 11.
6
Abaloparatide for the treatment of postmenopausal osteoporosis.阿巴洛肽用于治疗绝经后骨质疏松症。
Drugs Today (Barc). 2018 May;54(5):293-303. doi: 10.1358/dot.2018.54.5.2800621.
7
Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.阿巴洛肽（一种人甲状旁腺激素相关肽类似物）对绝经后骨质疏松症女性骨矿物质密度的影响。
J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.
8
The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA).年龄和骨密度对50-99岁绝经后女性骨折的绝对风险、额外风险及相对风险的影响：来自国家骨质疏松症风险评估（NORA）的结果
Osteoporos Int. 2006;17(4):565-74. doi: 10.1007/s00198-005-0027-4. Epub 2006 Jan 4.
9
Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.药物治疗绝经后骨质疏松症对骨密度和骨折率的疗效：网络荟萃分析。
Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2640-2668. doi: 10.26355/eurrev_201903_17414.
10
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.绝经后骨质疏松症患者使用阿巴洛肽治疗后的骨折发生率的地理分布。
Calcif Tissue Int. 2018 Jun;102(6):627-633. doi: 10.1007/s00223-017-0375-z. Epub 2017 Dec 28.
Zotero 插件